Healthline

Eylea vs Eylea HD: What's the Difference?

Eylea and the newer Eylea HD are both injectable medications used to treat certain serious eye conditions caused by abnormal blood vessel growth or leakage. The main difference between the two ...
Benzinga.com

FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...
WebMD

Treating Diabetic Macular Edema With Eylea

People with diabetic macular edema may get eye injections to help control their symptoms. These eye injections can improve vision and also stop the damage that causes vision to get worse. Most of ...
Seeking Alpha

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal ...
Seeking Alpha

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the ...
FiercePharma

Regeneron's Eylea HD passes key test in retinal vein occlusion, teeing up 2025 FDA filing as Eylea threats mount

With Eylea biosimilar competition creeping in and Roche’s Vabsymo jockeying for market share in key indications, Regeneron is racing to carve out a new market for the high-dose version of its ...
Healthline

Eylea and Eylea HD Dosing

Eylea and Eylea HD are prescription medications used to treat various eye conditions. The dosage and frequency of injections of these drugs vary based on the specific condition and the form of the ...
Nasdaq

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...
Business Insider

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...
Nasdaq

Regeneron Reports Eylea Sales, Provides Other Pipeline Updates

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14.
Mena FN

EYLEA HD® (Aflibercept) Injection 8 Mg Presentations At Angiogenesis 2026 Underscore Strength Of Its Clinical Profile For The Treatment Of Serious Retinal Diseases

(MENAFN- GlobeNewsWire - Nasdaq) New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase ...